DOI: 10.1055/s-00000054

Pharmacopsychiatry

Issue 04 · Volume 19 · July 1986 DOI: 10.1055/s-002-10188

Editorial

127
Delini-Stula, A.: 14th AGNP Meeting, Nürnberg 1985

Schizophrenia and Antipsychotic Drugs Introductory Papers

128
Heimann, H.: Models of Experience and Behavior in Psychotic Disorders

134
Delini-Stula, A.: Neuroanatomical, Neuropharmacological and Neurobiochemical Target Systems for Antipsychotic Activity of Neuroleptics
145
Langer, G.; Ackenheil, M.; Dixon, A. K.; Kurtz-May, G.; Möller, H. J.; Müller-Spahn, F.; Pietzcker, A.; Saletu, B.; Schönbeck, G.: The Psychopharmacology and Neuroendocrinology of Neuroleptics: The State of the Art from a Clinical Perspective
149
Christensen, A. V.; Greil, W.; Haag, H.; Havemann, U.; Kehr, W.; Kuschinsky, K.; Porsolt, R. D.; Rüther, E.; Tegeler, J.: Animal Models for Assessing Extrapyramidal-Motor Side-Effects of Neuroleptics
156
Möller, H. J.: Methodological Problems of Long-term Studies in Psychopharmacology
161
Pietzcker, A.; Gaebel, W.; Köpcke, W.; Linden, M.; Müller, P.; Müller-Spahn, F.; Schüssler, G.; Tegeler, J.: A German Multicenter Study on the Neuroleptic Long-term Therapy of Schizophrenic Patients
167
Greil, W.; Haag, M.; Huber, D.; Schmidt, St.: Maintenance Treatment in Affective Disorders: Overview and Design of a Collaborative Study
172
Fuhr, P.; von Luckner, N.; Woggon, B.: Can Pretreatment Data Predict Withdrawals in Clinical Trials of Psychotropic Drugs?
174
Woggon, B.; Biber, M.; Stassen, H. H.: Clinical Trials of Antidepressants: Have the Patient Samples Changed During the Years?
176
Bender, W.; Haag, M.; Haag, H.; Greil, W.; Engel, R.: Compliance in Psychiatry: Development of a Patient Questionnaire
178
Maier, W.; Philipp, M.; Schlegel, S.; Heuser, I.; Buller, R.; Frommberger, U.; Wetzel, H.; Wilhelmi, D.; Wittenborg, A.; Demuth, W.: Operational Diagnoses for Schizophrenic and Schizoaffective Disorders
180
Philipp, M.; Maier, W.; Frommberger, U.; Wilhelmi, D.; Wetzel, H.; Schlegel, S.; Buller, R.; Heuser, I.; Demuth, W.; Wittenborg, A.: Operational Diagnoses for Schizophrenic and Schizoaffective Disorders
182
Heuser, J.; Maier, W.: Depression, Melancholia, and Memory Recognition:
A Signal Detection Analysis
184
Schlegel, S.; Kretzschmar, K.: Computerized Tomographic Findings in Affective Disorder
186
Kohnen, R.; Krüger, H. P.: Drug Effects on Human Social Behavior:
Changes in Talking Activities Induced by CGP 361/A, a Beta-blocking Agent
188
Gaebel, W.; Ulrich, G.: Visuomotor Performance of Schizophrenic Patients and Normal Controls - I. Results of a Visual Fixation Task
190
Gaebel, W.; Ulrich, G.: Visuomotor Performance of Schizophrenic Patients and Normal Controls - II. Results of a Visual Search Task
192
Giedke, H.: Hibernation as a Model of Endogenous Depression
194
Filser, J. G.; Spira, F. J.; Gabel, A.; Beckmann, H.; Müller, W. E.: Comparative Determination of 3-Methoxy-4-Hydroxyphenylglycol and its Conjugated Derivatives in the Urine of Depressed Patients and Healthy Controls
196
Bohl, J.; Störkel, St.; Schulze, E.; Tschank, G.; Haas, St.; Krausbeck, E.; Gather, W.; Katzman, K.; Brocks, D.: Alzheimer's Disease: A Cerebral Amyloidosis
A Cooperative Study to Correlate Clinical, Biochemical and Pathologic-anatomical Findings
200
Ziegler, G.; Ludwig, L.; Fritz, G.: Effect of the Specific Benzodiazepine Antagonist Ro 15-1788 on Sleep
202
Renfordt, E.; Ulrich, G.: Relations among Psychopathology, Nonverbal Behavior (Speech Activity), and Neurophysiology (Topography of Alpha Power) under Antidepressive Drug Treatment
206
Dreher, A.; Baer-Degitz, M.; Köchert, R.; Nagel, L.; Salzer, W.-W.: Clinical Study of the Correlation Between the Antipsychotic Operative Dose of Perphenazine and Fine Motor Extrapyramidal Inhibition in Haase's Handwriting Test
210
Klieser, E.; Felgenträger, H. J.: Fluperlapine: A Therapeutic Alternative in Schizophrenic Psychoses
212
König, W.; Kunow, J.; Kniehl, R.; Reimer, F.: Neuroleptics in the Treatment of Schizophrenia: Have there been Changes in the Dosage Regimen?
214
Gutzmann, H.; Gaebel, W.; Linden, M.: One Year Follow-up of Schizophrenic Patients in Private Psychiatric Practice
216
Ruhland, M.; Fuchs, A. M.: Lack of Antagonism by Ro 15-1788 on Timelotem (KC 7507) - a Benzodiazepine with Antipsychotic and Anxiolytic Properties
218
Ruhland, M.; Tulp, M.; Muesch, H. R.; Fuchs, A. M.: Timelotem - an Antipsychotic Benzodiazepine Derivative
220
Ulrich, G.; Müller-Oerlinghausen, B.; Gaebel, W.: Changes in the Topographical Distribution of Absolute Alpha-power in the Resting EEG of Schizophrenic In-patients under Neuroleptic Medication
222
Gaebel, W.; Ulrich, G.: Topographical Distribution of Absolute Alpha-power in Schizophrenic Outpatients - On-drug Responders vs. Nonresponders
224
Wildenauer, D. B.; Bondy, B.; Welter, D.; Ackenheil, M.: The Phospholipid Composition of Lymphocytes in Schizophrenic Patients: Effect of Treatment with Neuroleptics
228
Naber, D.; Albus, M.; Bürke, H.; Müller-Spahn, F.; Münch, U.; Reinertshofer, T.; Wissmann, J.; Ackenheil, M.: Neuroleptic Withdrawal in Chronic Schizophrenia.
CT and Endocrine Variables are not Valid Predictors of Psychopathological Changes
230
Schreiber, W.; Kissling, W.; Möller, H. J.; Bäuml, J.; Gain, T.; Bottermann, P.: TRH-Test and Psychiatric Disorders
232
Mühlbauer, H. D.; Müller-Oerlinghausen, B.: Fenfluramine Stimulation of Morning Cortisol in Manic-depressive Patients and Lithium Prophylaxis: A Marker of (Auto-) Aggressiveness and Prophylactic Response?
233
Roncoroni, D.: Prolactin as an Index of Neuroleptic Effects on the Neuroendocrine Regulatory Activity of the Hypotalamic Pituitary System
235
Laakmann, G.; Neuhauser, H.; Hinz, A.; Neulinger, E.; Wittmann, M.: Stimulation of Growth Hormone, Prolactin, and Cortisol by GHRH and DMI in Depressed Patients
237
Laakmann, G.; Hinz, A.; Munz, T.; Schoen, H.-W.; Wittmann, M.; Zygan, K.: Interactions of Alpha-2/Beta Receptors and DMI-lnduced GH, PRL and Cortisol Stimulation
239
Laakmann, G.; Hinz, A.; Neulinger, E.; Strauss, A.; Wittmann, M.: DMI-Induced Growth Hormone Stimulation in Healthy Subjects and Depressed Patients
241
Mühlbauer, H. D.; Ziolko, H. U.: Abnormalities of Anterior Pituitary Responsiveness to Hypothalamic Hormones in Bulimia
245
Delini-Stula, A.; Hunn, Ch.: Effects of Imipramine and Brofaromine, a Selective and Reversible MAO-A Inhibitor, on Novelty-oriented Behaviour in Rats
247
Kapfhammer, H. P.; Hoff, P.; Golling, H.; Rüther, E.; Schmauss, M.: Cimoxatone and Moclobemide, Two New MAO-lnhibitors, in the Treatment of Major Depressive Disorder
249
Hoff, P.; Golling, H.; Kapfhammer, H. P.; Lund, R.; Pakesch, G.; Rüther, E.; Schmauss, M.: Cimoxaton and Moclobemid, Two New MAO-lnhibitors:
Influence on Sleep Parameters in Patients with Major Depressive Disorder
251
Schmauss, M.; Kapfhammer, H. P.; Meyr, P.; Hoff, P.: Combined MAO-inhibitor and Tri-(Tetra) Cyclic Antidepressant Treatment in Therapy Resistant Depression
253
Wendt, G.; Binz, U.; Fischer, E.: Long-term Treatment with Oxaprotiline in Patients with Endogenous Depression
255
Linden, M.; Schüssler, G.: Compliance and Treatment Outcome of Antidepressant Therapy in Private Psychiatric Practice
257
Boll, E.; Tarighati, M. A.; Holsboer, F.: Clinical Application of Antidepressant-Plasma Level Analysis with High Pressure Liquid Chromatography (HPCL)
259
Giedke, H.; Axmann, D.; Gaertner, H. J.; Rein, W.; Rötzer-Zimmer, F. T.: Psychophysiological Predictors of Antidepressant Therapy Response?
262
Philipp, M.; Beck, V.; Scherhag, R.; Glocke, M.; Schmidt, R.: Biological and Psychopathological Prediction of Response to Doxepine in Depressive Outpatients
264
Schmauss, M.; Laakmann, G.; Dieterle, D.: Yohimbine in Combination with Tricyclic Antidepressants in the Treatment of Therapy-Resistant Depressed Patients
266
Schmauss, M.; Laakmann, G.; Dieterle, D.: Influence of Nomifensine on Prolactin Secretion in Depressed Inpatients
268
Süss, St.; Boll, E.; Holsboer, F.: Urinary Multisteroid Analysis Applying Glass-capillary Gas-chromatography - A New Technique to Assess Adrenocortical Activity in Depression
270
Ulrich, G.; Renfordt, E.; Frick, K.: Electroencephalographic Dynamics of Vigilance and Drug-response in Endogenous Depression.
A Comparison of Patients Treated with Amitriptyline or Pirlindole
272
Ulrich, G.; Renfordt, E.; Frick, K.: The Topographical Distribution of Alpha-activity in the Resting EEG of Endogenous-depressive In-patients with and without Clinical Response to Pharmacotherapy
276
Calker, D. van; Greil, W.: Effects of Lithium Ions on the Metabolism of Phosphoinositides: Studies with Rat Pheochromocytoma Cells (PC-12 cells)
278
Haag, M.; Heidorn, A.; Haag, H.; Greil, W.: Response to Stabilising Lithium Therapy and Sequence of Affective Polarity
280
Möller, H. J.; Kissling, W.; Tavan, S.; Winter, I.: Is Carbamazepine Able to Increase the Antimanic Effect of Haloperidol?
282
Cabrera, J. F.; Mühlbauer, H. D.; Schley, J.; Stoll, K. D.; Müller-Oerlinghausen, B.: Long-term randomized Clinical Trial on Oxcarbazepine vs Lithium in Bipolar and Schizoaffective Disorders: Preliminary Results.
284
Müller-Oerlinghausen, B.; Imiela, M.: In-vitro and In-vivo Studies on the Pharmacokinetics and Clinical Efficacy of Lithium Aspartate as Compared to Conventional Lithium Preparations
286
Volk, J.; Müller-Oerlinghausen, B.: Time Course of AMP-Documented Side-effects in Patients under Long-term Lithium Treatment
290
Wastl, R.; Grohmann, R.; Rüther, E.: Frequency of Increased Serum Liver-enzyme Levels under Treatment with Neuroleptics
292
Dirschedl, P.; Grohmann, R.; Schmidt, L. G.: Reliability of Adverse Drug Reaction Assessment
294
Spieß-Kiefer, C.; Grohmann, R.; Rennig, E.; Rüther, E.; Scherer, J.; Schmidt, L. G.: Acute Delirious Syndromes due to Psychotropic Drugs
296
Wolf, B.; Rüther, E.; Brenner, P.-M.; Poser, W.; Schmidt, L. G.: Abuse of and Dependence on Stimulants and Anorexigenic Drugs in Psychiatric Inpatients
298
Bürke, H.; Grohmann, R.; Rüther, E.: Psychiatric Outpatient Treatment: Developing Methods of Drug Surveillance
300
Grohmann, R.; Dirschedl, P.; Rennig, E.; Scherer, J.; Schmidt, L. G.: Methodological Problems in Assessment of Adverse Drug Reactions with Drug Combinations
304
Bischoff, S.; Bruinink, A.; Krauss, J.; Schaub, M.; Vassout, A.: In Vivo and in Vitro Characterization of Dopamine Receptors in Hippocampus and their Pharmacological Relevance
306
Bischoff, S.; Vassout, A.; Delini-Stula, A.; Waldmeier, P.: Interactions of Cipazoxapine, Citatepine, Eresepine, and Maroxepine with Central Dopamine (DA) Receptors: Effects on in Vivo (3H)Spiperone Binding, DA Metabolism, and Behavioral Parameters
308
Fuchs, V.; Coper, H.: Kinetic Characteristics of Some Neuronal Receptors After Combined Treatment with Diazepam and Haloperidol
310
Heil, Th.; Jänicke, B.: The Influence of P-Hydroxy-norephedrine on "Drug-taking-behavior" to D-Amphetamine
312
Jänicke, B.; Schulze, G.: Capacity of Thermoregulation in Different Aged Rats: Age as a Factor Modifying Thermoregulation
314
Müller, W. E.; Groh, B.; Bub, O.; Hofmann, H. P.; Kreiskott, H.: In vitro and In vivo Studies of the Mechanism of Action of Arfendazam, a novel 1,5-Benzodiazepine
316
Waldmeier, P. C.; Bischoff, S.; Bittiger, H.; Hauser, K.; Vassout, A.; Delini-Stula, A.; Haeusler, A.; Schenkel, L.; Storni, A.: Pharmacological Profiles of Four New Tetracyclic Dopamine Antagonists, Maroxepine, Citatepine, Eresepine, and Cipazoxapine
318
Waldmeier, P. C.; Baumann, P. A.: Ifoxetine: An Unusual 5-HT Uptake Inhibitor or an Inhibitor of 5-HT Release?
322
Spiegel, R.; Berger, M.: Workshop on Pharmacological and Clinical Studies with Cholinergic Drugs in Humans
323
Azcona, A.; Roth, S.; Spiegel, R.: Effects of the Muscarinic Agonist RS 86 in Healthy Volunteers
326
Berger, M.; Krieg, J. C.; Rummler, R.; Raptis, C.; Morinigo, A.; Dose, M.; Benker, B.: The Treatment of Mania with the Cholinomimetic Drug RS 86
328
Tegeler, J.: Cholinergic Drugs for the Treatment of Tardive Dyskinesia
333
Kallus, K. W.: Agglutination of Single-case Data: Application to Individual Data in Experimental Designs
337
Frank, D. R.: Psychological Theories of the Effects of Placebos with Special Consideration for the Attribution Theory
339
Herz, A.: The Role of Opioid Peptides in Placebo-induced Effects
341
Maier, W.; Buller, R.; Philipp, M.; Frommberger, U.: Placebo-Controlled Long-Term Studies in Chronic Depressed Patients: Evaluation by Single-Case-Analyses
343
Laakmann, G.; Blaschke, D.: Use of Placebo in Clinical Trials on Therapeutic Efficacy of Newly Developed Drugs in Outpatients
345
Janke, W.: Consistency of Response to Placebo with Different Instructions
347
Saupe, R.: The Use of Placebo as Seen by Nursing Staff

Discusion groups

140
Bischoff, S.; Bürki, H. R.; Emrich, H. M.; Jaeckel, J.; Kornhuber, J.; Ruhland, M.; Schmid, W. J.; Woggon, B.: Biochemical and Molecular Mechanisms of Action of Neuroleptics, Alternatives to the Classical Dopamine Hypothesis: Minutes of the Discussion Group

Methodological Problems in Planning, Performing and Analysing of Long-Term Studies with psychotropic Drugs

152
Schou, M.: Methodological Problems of Prophylactic Trials in Recurrent Affective Illness
A Historical Perspective

Methodology of Clinical Trials

170
Haug, H.-J.; Fähndrich, E.: Problems in Defining Response in Therapy Studies

Pharmaco-EEG, Sleep,Neuropsychophysiology

198
Wiegand, M.; Berger, M.; Zulley, J.; von Zerssen, D.: The Effect of Trimipramine on Sleep in Patients with Major Depressive Disorder

Antipsychotic Drugs and Extrapyramidal Side-Effects

204
Woggon, B.; Beckmann, H.; Heinrich, K.; Linden, M.; Krebs, E.; Küfferle, B.; Pflug, B.; Rüther, E.; Schied, H. W.: Clinically Relevant Differences in the Therapeutic Profile of Fluperlapine Compared to Haloperidol in the Treatment of Schizophrenic Psychosis - Results of a Multicentre Double-blind Study

Antipsychotic Drugs:Clinical Studies and Psychophysiology

208
Gaebel, W.; Pietzcker, A.; Baumgartner, A.: 3-Year Follow-up of Schizophrenic Patients - Outcome Dimensions and Neuroleptic Treatment

Immunology and Neuroendocrinology in Psychic Disorders

226
Moises, H. W.; Beck, J.; Schindler, L.; Kirchner, H.: Decreased Interferon Production in Schizophrenic Patients

Antidepressant Drugs

243
Oefele, K. v; Grohmann, R.; Rüther, E.: Adverse Drug Reactions in Combined Tricyclic and MAOI Therapy

Lithium

274
Hegerl, U.; Ulrich, G.; Müller-Oerlinghausen, B.: Augmenting - Reducing Response to Auditory Evoked Potentials and its Relationship to the Prophylactic Effect of Lithium Salts

Adverse Drug Reactions(The AMüP Study Group)

288
Schmidt, L. G.; Grohmann, R.; Müller-Oerlinghausen, B.; Ochsenfahrt, H.: Tolerability and Safety of Antidepressant Drugs in Psychiatric In- and Out-patients Assessed by two Drug Surveillance Systems

Experimental Pharmacology

302
Bering, B.; Spira, F.; Schanz, H.; Gattaz, W. F.; Müller, W. E.: Do Human Erythrocyte Membranes Contain Muscarinic Cholinergic Receptors?

Drug Epidemiology

320
Koenig, W.; Rüther, E.; Filipiak, B.; Keil, U.: Determinants of Psychotropic Drug Intake in a Metropolitan Population

Workshop on One Case Experiments in Pharmacopsychiatry - Possibilities and Limitations

331
Wolf, G. K.: Basic Questions for the Use of Single Case Statistics

Workshop on New Aspects of the Placebo Problem

335
Netter, P.; Heck, S.; Müller, H. J.: What Selection of Patients is Achieved by Requesting Informed Consent in Placebo Controlled Drug Trials?